OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy-Oncolytics is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Ferroptosis gene signature in cholangiocarcinoma	246
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence	79
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models	55
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis	50
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1	46
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation	43
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma	39
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers	36
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML	36
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy	36
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer	33
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity	33
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer	33
PROTACs in gastrointestinal cancers	33
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity	32
Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response	32
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme	30
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy	30
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia	30
A library of cancer testis specific T cell receptors for T cell receptor gene therapy	29
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T	29
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia	28
Radiovirotherapy at twenty	27
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges	27
Adding recombinant AAVs to the cancer therapeutics mix	26

Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products